This is an open-label study, which means the treatment is known to the study team and the participants. People in the study will continue receiving AMG 732 for a period of time and will have regular study visits over the course of the trial. During these visits, the study team will check for any side effects and follow changes in the eye condition. The study is planned to run for a number of years.

Participants in the study will receive Batoclimab through a subcutaneous injection, which means it is injected under the skin. The treatment will be administered once a week for a total of 24 weeks. For the first 12 weeks, participants will receive a dose of 680 mg, followed by a reduced dose of 340 mg for the remaining 12 weeks. Some participants will receive a placebo, which looks like the treatment but does not contain the active substance.

The study aims to observe changes in the condition of the eyes, specifically looking at the reduction in eye protrusion, known as proptosis, by the end of the 24-week period. The trial will also monitor other aspects of the disease, such as changes in eye inflammation and overall eye health. The goal is to determine if Batoclimab can effectively improve symptoms of TED compared to the placebo.

The purpose of the study is to compare how well K1-70 works compared to placebo in reducing the bulging of the eyes in people with active thyroid eye disease. The main focus is to see if K1-70 can help decrease how much the eyes protrude forward by at least a certain amount after 24 weeks of treatment. The study will also look at other aspects of the disease, such as changes in eye muscle inflammation seen on MRI scans, improvements in quality of life, changes in disease activity scores, improvements in double vision, and changes in the volume of tissue behind the eye. Additionally, the study will monitor safety by checking for any side effects, measuring vital signs, performing heart tests with an ECG, conducting laboratory tests, and examining the eyes and overall health of participants.

Participants will receive K1-70 or placebo once every 6 weeks for a total of 24 weeks. The study will measure various outcomes throughout the treatment period and will continue to follow participants after the treatment is completed. The medication will be given at a dose of up to 100 milligrams per infusion, with a maximum total dose of 800 milligrams over the entire treatment period of 48 weeks. The study will also measure the levels of the medication in the blood over time and check for any immune responses to the treatment.

The purpose of the study is to find out if atorvastatin can prevent the development of active Graves ophthalmopathy in patients who have just been diagnosed with Graves’ disease. Participants will take atorvastatin tablets by mouth for a period of 12 months. The maximum daily dose will be 40 milligrams. During the study, patients will be monitored at several time points over 18 months to check if they develop eye problems and to measure the activity level of any eye inflammation using a scoring system. The study will also look at how the treatment affects quality of life and measure certain antibodies in the blood that are related to the disease.

Throughout the study period, researchers will collect information about whether patients need additional treatments for eye problems, such as corticosteroids or other medications. Blood samples will be analyzed to look for biological markers that might help predict who will respond well to the treatment. The study will also examine genetic differences between people who respond to atorvastatin and those who do not. Patients will complete questionnaires about their quality of life at the beginning of the study, after 12 months, and after 18 months to see how the treatment affects their daily living and well-being.

The purpose of the study is to compare how much of the imaging substance is taken up by the tissues around the eyes in patients who have active disease versus those who have inactive disease. Active disease means the condition is currently causing noticeable symptoms and changes, while inactive disease means the condition has been stable and quiet for at least six months. The study will involve patients receiving an injection of the imaging substance and then undergoing a PET scan combined with an MRI scan. A PET scan is a type of imaging that shows how tissues and organs are functioning by detecting the injected substance, while an MRI scan uses magnetic fields to create detailed pictures of the body’s internal structures.

During the study, researchers will examine the scan images to see how much of the substance accumulates in the eye tissues of patients with active disease compared to those with inactive disease. They will also look at how the scan results relate to other measurements such as swelling seen on the MRI, the symptoms patients are experiencing, and laboratory test results. This information may help doctors better understand and assess the activity level of the disease in future patients.

The purpose of the study is to evaluate how well teprotumumab works compared to placebo in reducing eye bulging in people with this condition, and to assess its safety and how well it is tolerated. The study will measure whether the eyes move back into a more normal position by at least 2 millimeters without the other eye getting worse. The study will also look at other aspects of the disease, including signs of inflammation, double vision, and how the condition affects quality of life.

Participants in this study will be randomly assigned to receive either teprotumumab or placebo through injections under the skin. The study will follow participants over a period of time to monitor changes in eye bulging, inflammation scores, double vision, and overall well-being. Participants must have active disease with significant eye bulging and symptoms that started within 15 months before joining the study. Their thyroid hormone levels should be controlled or only mildly abnormal during the study.

The purpose of this research is to investigate how well AMG 732 works in people with moderate to severe active Thyroid Eye Disease. The study will include both healthy volunteers and people with Thyroid Eye Disease. The medication or placebo will be given multiple times during the study to evaluate its effects on eye symptoms.

During the study, doctors will monitor changes in eye bulging (also called proptosis), eye movement, and vision. They will also track how the medication moves through the body and check for any side effects. Participants will complete questionnaires about their vision-related quality of life and appearance throughout the study period.

The treatment involves receiving five intravenous infusions of either VRDN-001 or placebo over several weeks. The medication will be given through a vein using a solution that contains sodium chloride (normal saline). Each infusion will be carefully prepared to contain the correct amount of medication based on the person’s weight.

During the study, doctors will measure changes in eye bulging (also called proptosis) and other eye-related symptoms. They will also monitor how well participants tolerate the treatment and track any side effects that may occur. The total duration of participation in the study will be approximately 12 weeks, during which participants will need to attend regular check-ups at the clinic.

The purpose of the study is to evaluate the safety, tolerability, and effectiveness of VRDN-001 in both healthy volunteers and individuals with TED. Participants will receive the medication through an intravenous infusion, which means it will be administered directly into the bloodstream. The study will last for a period of up to 56 days, during which participants will receive multiple doses of the medication. Throughout the study, researchers will monitor participants closely to assess how well the medication is working and to identify any potential side effects.

In addition to VRDN-001, some participants may receive a solution of Sodium Chloride, which is commonly used in medical settings. The study aims to gather important information about how VRDN-001 affects the body and its potential as a treatment for Thyroid Eye Disease. This research could lead to new insights and advancements in the management of this condition.

The purpose of the study is to determine if VRDN-003 is safe and tolerable for people with TED. Participants will receive the treatment as a series of injections, and the study will monitor how their bodies react to the medication. The study will also look at changes in the bulging of the eyes over time. A comparison will be made between the eye condition before starting the treatment and after 24 weeks of receiving the injections.

The study will last for a period of time, with the primary focus on observing any safety events that occur after starting treatment with VRDN-003. These observations will continue through Week 24, and further safety assessments will be made up to Week 52. The goal is to ensure that the treatment is not only effective but also safe for long-term use in managing Thyroid Eye Disease.

The purpose of the study is to determine if VRDN-003 is effective, safe, and tolerable for people with chronic TED. The study will last for several months, and participants will be monitored to see if there is a reduction in eye bulging and if their symptoms improve without worsening. The study will also look at any side effects that may occur and how the body responds to the treatment.

Throughout the study, researchers will assess the percentage of participants who show improvement in their condition by Week 24. This includes a reduction in eye bulging and no worsening of their disease severity. The study will also evaluate changes in symptoms like double vision and overall safety. The results will help determine if VRDN-003 can be a beneficial treatment option for those living with chronic TED.

The purpose of the study is to evaluate how effective and safe TOUR006 is in treating people with Thyroid Eye Disease. Participants in the study will receive either the new treatment or a placebo, which is a substance with no active medication. The study will last for several weeks, and participants will receive regular injections and attend follow-up visits to monitor their progress. The main goal is to see if the treatment can reduce the eye bulging by at least 2 millimeters without worsening the condition in the other eye.

Throughout the study, participants will be monitored for any changes in their condition, including improvements in eye bulging and other symptoms like double vision. The study will also track any side effects or adverse events that may occur. The results will help determine if TOUR006 is a viable treatment option for people with Thyroid Eye Disease.

Participants in the study will receive either the VRDN-003 injection or a placebo. The injections will be administered under the skin, either every four weeks or every eight weeks. The study will last for several months, during which the effects of the treatment on eye symptoms and overall health will be closely monitored. The main focus is to determine if there is a significant reduction in eye bulging and other symptoms by the end of the study period.

The study will also look at any side effects that may occur and how the body responds to the treatment. The aim is to gather comprehensive data on the effectiveness and safety of VRDN-003 for people with active TED. This information will help in understanding whether VRDN-003 could be a viable treatment option for managing the symptoms of Thyroid Eye Disease.

The purpose of the study is to evaluate how these treatments affect the activity and progression of Graves’ ophthalmopathy in patients who have mild to moderate symptoms. Participants will be involved in the study for a period of six months. During this time, the study will monitor changes in the condition’s activity and any progression to more severe forms. The study will also assess the quality of life of participants and examine specific markers related to the disease.

Throughout the study, participants will undergo various assessments to track the effects of the treatments. These assessments will include measuring the thickness of the conjunctiva, which is the clear tissue covering the white part of the eye, using a technique called optical coherence tomography. The study aims to provide valuable insights into the management of Graves’ ophthalmopathy and potentially improve treatment options for those affected by this condition.

Participants in the study will receive Batoclimab injections once a week for a total of 24 weeks. For the first 12 weeks, the dose will be 680 mg, and for the following 12 weeks, the dose will be reduced to 340 mg. Some participants will receive a placebo, which looks like the treatment but does not contain any active substance. The study aims to see if Batoclimab can help reduce the bulging of the eyes, known as proptosis, and improve other symptoms of Thyroid Eye Disease by the end of the 24-week period.

The study will monitor changes in eye symptoms and overall quality of life for participants. It will also look at how the treatment affects certain antibodies in the blood that are related to Thyroid Eye Disease. The goal is to determine if Batoclimab can provide significant relief from the symptoms of this condition compared to the placebo. Participants will be closely observed throughout the study to ensure their safety and to gather information on the treatment’s effectiveness.

The purpose of the study is to evaluate how effective Lu AG22515 is in reducing the bulging of the eyes, known as proptosis, in patients with moderate-to-severe TED. Participants in the study will receive the treatment over a period of time, and their progress will be monitored to see how the treatment affects their eye condition. The study will also look at how the body processes the treatment and check for any side effects or immune responses.

Throughout the study, participants will have regular check-ups to measure changes in their eye condition and overall health. The trial aims to provide valuable information on the potential benefits and safety of Lu AG22515 for people living with moderate-to-severe Thyroid Eye Disease.

The purpose of the study is to assess how effective efgartigimod is in treating TED by looking at the change in eye symptoms over a 24-week period. The study will involve regular check-ups and assessments to monitor the participants’ progress and any changes in their condition. The main focus will be on the reduction of eye bulging, known as proptosis, and improvements in the quality of life related to eye health. Participants will be randomly assigned to receive either the active treatment or the placebo, and neither the participants nor the researchers will know who is receiving which treatment during the study period.

Throughout the study, participants will be closely monitored for any side effects or changes in their condition. The study aims to provide valuable information on the safety and effectiveness of efgartigimod for people with TED, potentially leading to better treatment options in the future. The trial is expected to continue until 2027, with recruitment starting in 2024.

The purpose of the study is to assess how well Efgartigimod works in reducing symptoms of Thyroid Eye Disease, particularly focusing on the reduction of eye bulging, known as proptosis, over a 24-week period. Participants in the study will receive either Efgartigimod or a placebo through subcutaneous injections, which means the injection is given under the skin. The study will monitor changes in eye symptoms and overall quality of life during this time.

Participants will be adults diagnosed with active, moderate-to-severe Thyroid Eye Disease. The study will involve regular visits to monitor the effects of the treatment and ensure the safety and well-being of the participants. The trial aims to provide valuable information on whether Efgartigimod can be a beneficial treatment option for those affected by this condition.

Throughout the study, participants will receive the treatment through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will last for a period of up to 24 weeks, during which time participants will be closely monitored by healthcare professionals. The study aims to observe changes in the symptoms of Thyroid Eye Disease, such as eye bulging and other related eye issues, to determine if LASN01 is effective in reducing these symptoms.

Participants will undergo regular check-ups, including physical examinations and laboratory tests, to ensure their safety and to monitor any potential side effects of the treatment. The study will also involve measuring the concentration of LASN01 in the blood at various times to understand how the body processes the medication. This research is important for developing new treatments that could improve the quality of life for people with Thyroid Eye Disease.

The purpose of this study is to provide access to VRDN-001 for participants who did not respond to previous treatments in earlier studies. The study will assess the safety and effectiveness of VRDN-001 in these participants. Participants will receive the treatment through an intravenous infusion, which means the medication will be given directly into a vein. The study will last for a period of 12 weeks, during which participants will receive several doses of the medication.

Throughout the study, participants will be monitored for any changes in their condition, as well as any side effects they may experience. The study aims to determine if VRDN-001 can help reduce the symptoms of Thyroid Eye Disease in those who have not responded to other treatments. Participants will be closely observed to ensure their safety and to gather information on how well the treatment works.

Participants in the study will receive either Sirolimus or Methylprednisolone over a period of 12 months. The study will monitor changes in the condition of the eyes, such as a reduction in the Clinical Activity Score (CAS), which measures the activity of the disease, and improvements in eye symptoms like proptosis (bulging of the eyes) and lid retraction (pulling back of the eyelids). The study will also assess improvements in eye movement and overall quality of life related to the eye condition.

The trial aims to provide valuable information on the effectiveness and safety of Sirolimus compared to corticosteroids in treating active Thyroid Eye Disease. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the outcomes of the treatments. The results of this study could potentially lead to better treatment options for individuals affected by this eye condition.

The purpose of the study is to evaluate the safety and tolerability of different durations of treatment with Teprotumumab in patients with Thyroid Eye Disease. Participants will be randomly assigned to receive either the medication or the placebo. The study will monitor how patients respond to the treatment over time, including any side effects they may experience. The trial will also assess whether patients need to be treated again after the initial treatment period.

Throughout the study, participants will have regular check-ups to monitor their condition and the effects of the treatment. These check-ups will include measurements of eye symptoms and overall health assessments. The study aims to provide valuable information on how well Teprotumumab works for treating Thyroid Eye Disease and how long the treatment should last for the best results.

The purpose of the study is to evaluate the safety and effectiveness of Linsitinib in treating TED. Participants will be randomly assigned to receive either Linsitinib or a placebo. The study will last for 24 weeks, during which time the effects of the medication on eye symptoms will be closely monitored. The main focus will be on changes in eye bulging, known as proptosis, and other symptoms related to TED.

Throughout the study, participants will have regular check-ups to assess their response to the treatment. The study aims to determine if Linsitinib can reduce the severity of TED symptoms and improve the quality of life for those affected by this condition. The results will help understand the potential benefits of Linsitinib for people with TED.

Participants in this study have previously completed another study involving Batoclimab. This extension study allows researchers to continue monitoring the effects of the treatment over a longer period. The study involves regular injections of Batoclimab and periodic assessments to track the progress of the treatment. Participants will not undergo any immediate surgical interventions or other medical therapies for TED during the study period.

The study aims to understand how long the positive effects of Batoclimab last after stopping the treatment and to evaluate the proportion of participants who respond to the treatment. This information will help determine the long-term benefits and safety of Batoclimab for individuals with Thyroid Eye Disease.

The purpose of the study is to assess the effectiveness and safety of linsitinib in individuals with moderate to severe TED. Participants in the study will receive either linsitinib or a placebo, which is a tablet that looks like the medication but does not contain the active ingredient. The study will last for 24 weeks, during which participants will take the medication and have regular check-ups to monitor their condition and any changes in their symptoms.

Throughout the study, researchers will focus on measuring the change in eye bulging and other symptoms to determine how well linsitinib works. The goal is to find out if linsitinib can provide relief for people with TED by reducing the severity of their symptoms without causing significant side effects. This study is an extension of previous research and aims to provide more information on the potential benefits of linsitinib for those affected by this eye condition.

The purpose of this study is to confirm the safety and tolerability of VRDN-001 in people with TED. Participants in the study will receive five doses of VRDN-001 through an intravenous infusion, which means the medication is given directly into a vein. Each dose will be administered every three weeks. The study will monitor participants for any side effects and changes in their condition over a period of time.

Throughout the study, researchers will be looking at how participants respond to the treatment, including any changes in the symptoms of TED, such as the degree of eye bulging. The study aims to gather important information about the safety of VRDN-001 and how well it is tolerated by people with TED. This information will help in understanding the potential benefits and risks of using VRDN-001 as a treatment for this condition.